Abstract
Objective
The aim of this study is to summarize preclinical studies on herbal medicines used to treat cancer cachexia and its underlying mechanisms.
Methods
We searched four representing databases, including PubMed, EMBASE, the Allied and Complementary Medicine Database, and the Web of Science up to December 2016. Randomized animal studies were included if the effects of any herbal medicine were tested on cancer cachexia. The methodological quality was evaluated by the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADE) checklist.
Results
A total of fourteen herbal medicines and their compounds were identified, including Coptidis Rhizoma, berberine, Bing De Ling, curcumin, Qing-Shu-Yi-Qi-Tang, Scutellaria baicalensis, Hochuekkito, Rikkunshito, hesperidin, atractylodin, Sipjeondaebo-tang, Sosiho-tang, Anemarrhena Rhizoma, and Phellodendri Cortex. All the herbal medicines, except curcumin, have been shown to ameliorate the symptoms of cancer cachexia through anti-inflammation, regulation of the neuroendocrine pathway, and modulation of the ubiquitin proteasome system or protein synthesis.
Conclusions
This study showed that herbal medicines might be a useful approach for treating cancer cachexia. However, more detailed experimental studies on the molecular mechanisms and active compounds are needed.
概要
本综述总结利用中草药治疗癌症恶病质的临床前 研究及其潜在的机制,是首个针对中草药治疗癌 症恶病质动物模型成效进行系统性回顾评价的 研究。本文通过检索PubMed、EMBASE、Allied and Complementary Medicine Database 以及Web of Science 四大代表性的资料库(检索时间至2016 年12 月),就中草药治疗癌症恶病质的随机对 照动物试验进行系统性回顾分析, 并采用 CAMARADE 评分清单进行质量评价。分析结果 显示:在十四项中草药及其化合物中,除了姜黄 素外其他如黄连、黄连素、病得灵、清暑益气汤、 黄芩、补中益气汤、六君子汤、橙皮苷、苍术呋 喃烃、十全大补汤、小柴胡汤、知母及黄柏等都 已被证实可以通过抗炎、调节神经内分泌途径、 调节泛素蛋白酶体系统或蛋白质合成来改善癌 症恶病质的症状。因此,利用中草药治疗癌症恶 病质是一种有效的方法。然而该结论尚需要有更 详细的分子机制和活性化合物的实验研究验证。
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agyemang K, Han LF, Liu EW, et al., 2013. Recent advances in Astragalus membranaceus anti-diabetic research: pharmacological effects of its phytochemical constituents. Evid Based Complement Alternat Med, 2013:654643. https://doi.org/10.1155/2013/654643
Argilés JM, Anguera A, Stemmler B, 2013. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin Nutr, 32(3):319–324. https://doi.org/10.1016/j.clnu.2013.01.004
Beckett DM, Pycha K, Berg T, 2008. Effects of curcumin on tumor growth and muscle mass in a mouse model of cancer cachexia. Oncol Nurs Forum, 35(3):455–459. https://doi.org/10.1188/08.onf.455-45.
Blum D, Stene GB, Solheim TS, et al., 2014. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol, 25(8):1635–1642. https://doi.org/10.1093/annonc/mdu086
Brown JK, 2002. A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia. Oncol Nurs Forum, 29(3):517–532. https://doi.org/10.1188/02.ONF.517-53.
Chen YJ, Wu YX, Wang HX, et al., 2012. A new 9-noratractylodin from Atractylodes lancea and the antibacterial activity of the atractylodin derivatives. Fitoterapia, 83(1):199–203. https://doi.org/10.1016/j.fitote.2011.10.015
Cho WCS, Leung KN, 2007a. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett, 252(1): 43–54. https://doi.org/10.1016/j.canlet.2006.12.001
Cho WCS, Leung KN, 2007b. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol, 113(1):132–141. https://doi.org/10.1016/j.jep.2007.05.020
Choi YK, Jung KY, Woo SM, et al., 2014. Effect of Sipjeondaebotang on cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice. Mediators Inflamm, 2014:736563. https://doi.org/10.1155/2014/736563
Choi YY, Kim MH, Cho IH, et al., 2013. Inhibitory effect of Coptis chinensis on inflammation in LPS-induced endotoxemia. J Ethnopharmacol, 149(2):506–512. https://doi.org/10.1016/j.jep.2013.07.008
Chou YJ, Kuo CY, Chen PY, et al., 2012. Oral administration of Qing-Shu-Yi-Qi-Tang reduce lung cancer-induced cachexia in mice. Afr J Pharm Pharmacol, 6(2):84–91. https://doi.org/10.5897/AJPP11.186
Crawford J, Prado CMM, Johnston MA, et al., 2016. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep, 18(6):37. https://doi.org/10.1007/s11912-016-0522-0
Davis M, Lasheen W, Walsh D, et al., 2012. A phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manage, 43(1):78–86. https://doi.org/10.1016/j.jpainsymman.2011.03.007
Del Fabbro E, Dev R, Hui D, et al., 2013a. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol, 31(10):1271–1276. https://doi.org/10.1200/JCO.2012.43.6766
Del Fabbro E, Garcia JM, Dev R, et al., 2013b. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebocontrolled trial. Support Care Cancer, 21(9):2599–2607. https://doi.org/10.1007/s00520-013-1832-5
Devassy JG, Nwachukwu ID, Jones PJH, 2015. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev, 73(3):155–165. https://doi.org/10.1093/nutrit/nuu064
Dobs AS, Boccia RV, Croot CC, et al., 2013. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol, 14(4):335–345. https://doi.org/10.1016/S1470-2045(13)70055-X
Dong HY, He LC, Huang M, et al., 2008. Anti-inflammatory components isolated from Atractylodes macrocephala Koidz. Nat Prod Res, 22(16):1418–1427. https://doi.org/10.1080/14786410801931629
Evans WJ, Morley JE, Argilés J, et al., 2008. Cachexia: a new definition. Clin Nutr, 27(6):793–799. https://doi.org/10.1016/j.clnu.2008.06.013
Fearon K, Strasser F, Anker SD, et al., 2011. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7
Feng YB, Luo WQ, Zhu SQ, 2008. Explore new clinical application of Huanglian and corresponding compound prescriptions from their traditional use. China J Chin Mater Med, 33(10):1221–1225 (in Chinese).
Fu J, Wang ZH, Huang LF, et al., 2014. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res, 28(9): 1275–1283. https://doi.org/10.1002/ptr.5188
Fujitsuka N, Uezono Y, 2014. Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front Pharmacol, 5:271. https://doi.org/10.3389/fphar.2014.00271
Fujitsuka N, Asakawa A, Hayashi M, et al., 2009. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biol Psychiatry, 65(9):748–759. https://doi.org/10.1016/j.biopsych.2008.10.031
Fujitsuka N, Asakawa A, Uezono Y, et al., 2011. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry, 1(7):e23. https://doi.org/10.1038/tp.2011.25
Ghosh S, Banerjee S, Sil PC, 2015. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol, 83: 111–124. https://doi.org/10.1016/j.fct.2015.05.022
He Y, Yue Y, Zheng X, et al., 2015. Curcumin, inflammation, and chronic diseases: how are they linked? Molecules, 20(5):9183–9213. https://doi.org/10.3390/molecules20059183
Hong DS, Hui D, Bruera E, et al., 2014. MABp1, a firstin-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol, 15(6):656–666. https://doi.org/10.1016/S1470-2045(14)70155-X
Iizuka N, Miyamoto K, Hazama S, et al., 2000. Anticachectic effects of Coptidisrhizoma, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett, 158(1):35–41. https://doi.org/10.1016/s0304-3835(00)00496-1
Iizuka N, Hazama S, Yoshimura K, et al., 2002. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer, 99(2):286–291. https://doi.org/10.1002/ijc.10338
Ikegami F, Sumino M, Fujii Y, et al., 2006. Pharmacology and toxicology of Bupleurum root-containing Kampo medicines in clinical use. Hum Exp Toxicol, 25(8):481–494. https://doi.org/10.1191/0960327106het654oa
Iranshahi M, Rezaee R, Parhiz H, et al., 2015. Protective effects of flavonoids against microbes and toxins: the cases of hesperidin and hesperetin. Life Sci, 137:125–132. https://doi.org/10.1016/j.lfs.2015.07.014
Jang SE, Jeong JJ, Hyam SR, et al., 2013. Anticolitic effect of the rhizome mixture of Anemarrhena asphodeloides and Coptidis chinensis (AC-mix) in mice. Biomol Ther, 21(5): 398–404. https://doi.org/10.4062/biomolther.2013.048
Jeong JS, Ryu BH, Kim JS, et al., 2010. Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther, 9(4):331–338. https://doi.org/10.1177/1534735410383170
Kim A, Im M, Ma JY, 2016. Sosiho-tang ameliorates cachexiarelated symptoms in mice bearing colon 26 adenocarcinoma by reducing systemic inflammation and muscle loss. Oncol Rep, 35(3):1841–1850. https://doi.org/10.3892/or.2015.4527
Kumar A, Ekavali, Chopra K, et al., 2015. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol, 761:288–297. https://doi.org/10.1016/j.ejphar.2015.05.068
Lee AJ, Lee HJ, Kim JD, et al., 2014. Changes of peripheral blood lymphocyte subtypes in patients with end stage cancer administered localized radiotherapy and bojungikkitang. Evid Based Complement Alternat Med, 2014: 207613. https://doi.org/10.1155/2014/207613
Lenk K, Palus S, Schur R, et al., 2013. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle, 4(1):63–69. https://doi.org/10.1007/s13539-012-0085-3
Lesniak W, Bala M, Jaeschke R, et al., 2008. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Pol Arch Med Wewn, 118(11):636–644.
Li CQ, He LC, Dong HY, et al., 2007. Screening for the antiinflammatory activity of fractions and compounds from Atractylodes macrocephala Koidz. J Ethnopharmacol, 114(2):212–217. https://doi.org/10.1016/j.jep.2007.08.002
Li CR, Lin G, Zuo Z, 2011. Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharm Drug Dispos, 32(8):427–445. https://doi.org/10.1002/bdd.771
Li XX, Qu L, Dong YZ, et al., 2014. A review of recent research progress on the astragalus genus. Molecules, 19(11): 18850–18880. https://doi.org/10.3390/molecules191118850
Ma CH, Fan MS, Tang YH, et al., 2008. Identification of major alkaloids and steroidal saponins in rat serum by HPLCdiode array detection-MS/MS following oral administration of Huangbai-Zhimu herb-pair extract. Biomed Chromatogr, 22(8):835–850. https://doi.org/10.1002/bmc.1000
Mantovani G, Macciò A, Massa E, et al., 2001. Managing cancer-related anorexia/cachexia. Drugs, 61(4):499–514. https://doi.org/10.2165/00003495-200161040-0000.
Matsumoto T, Sakurai MH, Kiyohara H, et al., 2000. Orally administered decoction of Kampo (Japanese herbal) medicine, “Juzen-Taiho-To” modulates cytokine secretion and induces NKT cells in mouse liver. Immunopharmacology, 46(2):149–161. https://doi.org/10.1016/S0162-3109(99)00166-6
Mendes MC, Pimentel GD, Costa FO, et al., 2015. Molecular and neuroendocrine mechanisms of cancer cachexia. J Endocrinol, 226(3): R29-R43. https://doi.org/10.1530/JOE-15-017.
Mogami S, Hattori T, 2014. Beneficial effects of rikkunshito, a Japanese kampo medicine, on gastrointestinal dysfunction and anorexia in combination with Western drug: a systematic review. Evid Based Complement Alternat Med, 2014:519035. https://doi.org/10.1155/2014/519035
Muluye RA, Bian YH, Alemu PN, 2014. Anti-inflammatory and antimicrobial effects of heat-clearing Chinese herbs: a current review. J Tradit Complement Med, 4(2):93–98. https://doi.org/10.4103/2225-4110.126635
Muscaritoli M, Anker SD, Argilés J, et al., 2010. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr, 29(2):154–159. https://doi.org/10.1016/j.clnu.2009.12.004
Nahata M, Saegusa Y, Sadakane C, et al., 2014. Administration of exogenous acylated ghrelin or rikkunshito, an endogenous ghrelin enhancer, improves the decrease in postprandial gastric motility in an acute restraint stress mouse model. Neurogastroenterol Motil, 26(6):821–831. https://doi.org/10.1111/nmo.12336
Naksuriya O, Okonogi S, Schiffelers RM, et al., 2014. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials, 35(10):3365–3383. https://doi.org/10.1016/j.biomaterials.2013.12.090
Neary NM, Small CJ, Wren AM, et al., 2004. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab, 89(6):2832–2836. https://doi.org/10.1210/jc.2003-03176.
Niu GL, Tan J, Turner JG, et al., 2000. Bing de ling, a Chinese herbal formula, stimulates multifaceted immunologic responses in mice. DNA Cell Biol, 19(8):515–520. https://doi.org/10.1089/10445490050128449
Ohbuchi K, Nishiumi S, Fujitsuka N, et al., 2015. Rikkunshito ameliorates cancer cachexia partly through elevation of glucarate in plasma. Evid Based Complement Alternat Med, 2015:871832. https://doi.org/10.1155/2015/871832
Parhiz H, Roohbakhsh A, Soltani F, et al., 2015. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res, 29(3):323–331. https://doi.org/10.1002/ptr.5256
Pascual López A, Roqué I Figuls M, Urrutia Cuchi G, et al., 2004. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage, 27(4):360–369. https://doi.org/10.1016/j.jpainsymman.2003.09.007
Penet MF, Bhujwalla ZM, 2015. Cancer cachexia, recent advances, and future directions. Cancer J, 21(2):117–122. https://doi.org/10.1097/PPO.0000000000000100
Raghavendra V, Kulkarni SK, 2000. Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT2A receptor-mediated activation of HPA axis. Brain Res, 860(1–2): 112–118. https://doi.org/10.1016/S0006-8993(00)02031-X
Rattanasompattikul M, Molnar MZ, Lee ML, et al., 2013. Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebocontrolled trial. J Cachexia Sarcopenia Muscle, 4(4): 247–257. https://doi.org/10.1007/s13539-013-0115-9
Ru WW, Wang DL, Xu YP, et al., 2015. Chemical constituents and bioactivities of Panax ginseng (C. A. Mey.). Drug Discov Ther, 9(1):23–32. https://doi.org/10.5582/ddt.2015.01004
Saegusa Y, Takeda H, Muto S, et al., 2011. Decreased plasma ghrelin contributes to anorexia following novelty stress. Am J Physiol Endocrinol Metab, 301(4):e685–E696. https://doi.org/10.1152/ajpendo.00121.2011
Saegusa Y, Hattori T, Nahata M, et al., 2015. A new strategy using rikkunshito to treat anorexia and gastrointestinal dysfunction. Evid Based Complement Alternat Med, 2015: 364260. https://doi.org/10.1155/2015/364260
Saiki I, 2000. A Kampo medicine “Juzen-taiho-to”: prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull, 23(6): 677–688. https://doi.org/10.1248/bpb.23.677
Shanmugam MK, Rane G, Kanchi MM, et al., 2015. The multifaceted role of curcumin in cancer prevention and treatment. Molecules, 20(2):2728–2769. https://doi.org/10.3390/molecules20022728
Strasser F, Lutz TA, Maeder MT, et al., 2008. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebocontrolled, double-blind, double-crossover study. Br J Cancer, 98(2):300–308. https://doi.org/10.1038/sj.bjc.6604148
Takahashi Y, Soejima Y, Kumagai A, et al., 2014. Japanese herbal medicines shosaikoto, inchinkoto, and juzentaihoto inhibit high-fat diet-induced nonalcoholic steatohepatitis in db/db mice. Pathol Int, 64(10):490–498. https://doi.org/10.1111/pin.12199
Takeda H, Sadakane C, Hattori T, et al., 2008. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology, 134(7):2004–2013. https://doi.org/10.1053/j.gastro.2008.02.078
Takeda H, Muto S, Hattori T, et al., 2010. Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology, 151(1):244–252. https://doi.org/10.1210/en.2009-063.
Tang YH, Sun ZL, Fan MS, et al., 2012. Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice. Planta Med, 78(1):18–23. https://doi.org/10.1055/s-0031-128026.
Tatsuta M, Iishi H, 1993. Effect of treatment with Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther, 7(4):459–462. https://doi.org/10.1111/j.1365-2036.1993.tb00120.x
Terawaki K, Sawada Y, Kashiwase Y, et al., 2014. New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am J Physiol Endocrinol Metab, 306(4):e373–E387. https://doi.org/10.1152/ajpendo.00116.2013
Teunissen SCCM, Wesker W, Kruitwagen C, et al., 2007. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage, 34(1): 94–104. https://doi.org/10.1016/j.jpainsymman.2006.10.015
Tisdale MJ, 1997. Biology of cachexia. J Natl Cancer Inst, 89(23):1763–1773. https://doi.org/10.1093/jnci/89.23.1763
von Haehling S, Anker SD, 2015. Treatment of cachexia: an overview of recent developments. Int J Cardiol, 184: 736–742. https://doi.org/10.1016/j.ijcard.2014.10.026
Wang H, Chan YL, Li TL, et al., 2012. Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang. Eur J Cancer, 48(7): 1074–1084. https://doi.org/10.1016/j.ejca.2011.06.048
Wang N, Tan HY, Li L, et al., 2015. Berberine and Coptidis Rhizoma as potential anticancer agents: recent updates and future perspectives. J Ethnopharmacol, 176:35–48. https://doi.org/10.1016/j.jep.2015.10.028
Wen HS, Li X, Cao YZ, et al., 2012. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy, 58(6):461–467. https://doi.org/10.1159/000346446
Wu X, Zhang HJ, Salmani JMM, et al., 2016. Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors. OncoTargets Ther, 9: 2935–2943. https://doi.org/10.2147/OTT.S105586
Xu Q, Brabham JG, Zhang SM, et al., 2005. Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model. DNA Cell Biol, 24(7): 470–475. https://doi.org/10.1089/dna.2005.24.470
Yae S, Takahashi F, Yae T, et al., 2012. Hochuekkito (TJ-41), a Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. Evid Based Complement Alternat Med, 2012:976926. https://doi.org/10.1155/2012/976926
Yamada C, Saegusa Y, Nakagawa K, et al., 2013. Rikkunshito, a Japanese Kampo medicine, ameliorates decreased feeding behavior via ghrelin and serotonin 2B receptor signaling in a novelty stress murine model. BioMed Res Int, 2013:792940. https://doi.org/10.1155/2013/792940
Yanagihara S, Kobayashi H, Tamiya H, et al., 2013. Protective effect of hochuekkito, a Kampo prescription, against ultraviolet B irradiation-induced skin damage in hairless mice. J Dermatol, 40(3):201–206. https://doi.org/10.1111/1346-8138.12050
Yang SH, Kao TI, Chiang BL, et al., 2015. Immune-modulatory effects of Bu-Zhong-Yi-Qi-Tang in ovalbumin-induced murine model of allergic asthma. PLoS ONE, 10(6): e0127636. https://doi.org/10.1371/journal.pone.0127636
Yao HT, Chang YW, Uramaru N, et al., 2012. Effects of Bu-Zhong-Yi-Qi-Tang on hepatic drug-metabolizing enzymes and plasma tolbutamide concentration in rats. J Ethnopharmacol, 142(1):121–128. https://doi.org/10.1016/j.jep.2012.04.024
Yennurajalingam S, Willey JS, Palmer JL, et al., 2012. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med, 15(10):1059–1064. https://doi.org/10.1089/jpm.2012.0146
Zhang JB, Zhuang PW, Wang Y, et al., 2014. Reversal of muscle atrophy by Zhimu-Huangbai herb-pair via Akt/mTOR/FoxO3 signal pathway in streptozotocin-induced diabetic mice. PLoS ONE, 9(6):e100918. https://doi.org/10.1371/journal.pone.0100918
Zhang Y, Dong H, Li Z, et al., 2010. Bing De Ling, a Chinese herbal formula, inhibits cancer cells growth via p53. Front Biosci, 2:221–230.
Zhuang PW, Zhang JB, Wang Y, et al., 2016. Reversal of muscle atrophy by Zhimu and Huangbai herb pair via activation of IGF-1/Akt and autophagy signal in cancer cachexia. Support Care Cancer, 24(3):1189–1198. https://doi.org/10.1007/s00520-015-2892-5
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Korea Institute of Oriental Medicine (Nos. K18041 (SSY) and K18043 (MSL)) and the Basic Science Research Program Through the National Research Foundation (NRF) of Korea (Nos. NRF-2015R1D1A1A02062410 (SSY) and NRF-2017R1A2B 4005357 (JYC))
Introducing editorial board member:
Prof. Myeong Soo LEE is a principal researcher of the Korea Institute of Oriental Medicine (KIOM), Daejeon, Republic of Korea. He received his PhD degree in 2004 from the Professional Graduate School of Oriental Medicine, Wonkwang University, Republic of Korea. He studied evidence-based medicine for complementary medicine at the Complementary Medicine, Peninsula Medical School, UK, for three years as visiting researcher. He is an adjunct professor at London South Bank University, UK and Tianjin University of Traditional Chinese Medicine, China. He is a founding member of the International Society of Complementary Medicine Research and a board member from 2011 to 2016 and from 2018 to 2020. He is also an advisory board member of the Cochrane Collaboration Complementary and Alternative Medicine (CAM) Field, University of Maryland, USA. He is working as a member of RIGHT (Essential Reporting Items for Practice Guidelines in Healthcare) group (http://www.right-statement.org/home/ member). He is the co-chair of Clinical Studies interest groups in Good Practice in the Traditional Chinese Medicine Research Association.
He is Associate Editor of the European Journal of Integrative Medicine and the Journal of Alternative and Complementary Medicine, and Section Editor of Medicine (Lippincott Williams & Wilkins). He is also working as an editorial board member in Journal of Zhejiang University-SCINECE B (Biomedicine & Biotechnology), Complementary Therapies in Medicine, Complementary Therapies in Clinical Practice, Maturitas, Chinese Medical Journal, Journal of Ginseng Research, Chinese Journal of Integrative Medicine, American Journal of Chinese Medicine, Journal of Traditional Chinese Medicine, Journal of Evidence Based Medicine, and several other professional journals. He was on the International Board of BMJ Fellows in 2014. He has published over 450 articles including original papers, reviews, and book chapters related to CAM, integrative medicine and mind-body medicine fields as leading or co-author.
Rights and permissions
About this article
Cite this article
Park, B., You, S., Cho, W.C.S. et al. A systematic review of herbal medicines for the treatment of cancer cachexia in animal models. J. Zhejiang Univ. Sci. B 20, 9–22 (2019). https://doi.org/10.1631/jzus.B1800171
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1800171